Therapix Biosciences’s Chief Executive Officer Dr. Elran Haber will step down from his position to pursue other professional opportunities.
The company’s Board of Directors is undertaking a search to identify a permanent, U.S. based Chief Executive Officer. Dr. Haber will continue to serve in his position while the search for a new Chief Executive Officer takes place.
“On behalf of the Therapix Board of Directors, I would like to thank Dr. Haber for his extraordinary service to our Company. Therapix made considerable progress under his leadership, including a successful U.S. initial public offering, and significant advancement in the Company’s clinical development programs,” commented Dr. Ascher Shmulewitz, Chairman of the Board of Therapix.